What Happened to Bayer Afrin Original Nasal Spray 6 mL Travel Size Recall?
Bayer HealthCare LLC initiated a voluntary recall of approximately 786,100 unexpired 6 mL travel-size bottles of Afrin Original Nasal Spray on April 30, 2026. The recall was prompted by the product's packaging failing to meet child-resistant standards and lacking required labeling under the Poison Prevention Packaging Act, posing a serious child poisoning risk. No injuries have been reported to date.
Quick Answer
On April 30, 2026, Bayer HealthCare LLC recalled about 786,100 travel-size (6 mL) bottles of Afrin Original Nasal Spray because their packaging was not child-resistant and lacked proper labeling, violating federal safety standards. This poses a risk of serious injury or illness from child poisoning if ingested. Consumers are advised to immediately secure the recalled bottles, stop using them, and request a refund through Bayer's dedicated webform.
📊Key Facts
📅Complete Timeline8 events
Recall of Oxymetazoline HCl Nasal Spray Due to Contamination
An over-the-counter oxymetazoline HCl 0.05% nasal spray (not Afrin branded) was recalled due to contamination with Burkholderia cepacia complex, posing risks of serious infection.
Recall of Oxymetazoline Hydrochloride Due to Microbial Contamination Concerns
A Class II recall was initiated for oxymetazoline hydrochloride nasal spray (not Afrin branded) due to possible microbial contamination in purified water used during manufacturing, though no contamination was found in final products.
Start of Sales for Recalled Afrin Travel Size Bottles
Bayer HealthCare LLC began selling the 6 mL travel-size Afrin Original Nasal Spray bottles that would later be subject to recall.
End of Sales for Recalled Afrin Travel Size Bottles
Sales of the non-compliant 6 mL travel-size Afrin Original Nasal Spray bottles continued until April 2026.
Bayer and CPSC Announce Voluntary Recall of Afrin Travel Size Nasal Spray
Bayer HealthCare LLC, in coordination with the U.S. Consumer Product Safety Commission, announced the voluntary recall of approximately 786,100 unexpired 6 mL travel-size Afrin Original Nasal Spray bottles. The recall was due to the packaging not being child-resistant and lacking required labeling under the Poison Prevention Packaging Act.
Recall Details and Remedy Provided to Consumers
Bayer provided instructions for consumers to secure recalled bottles, stop use, and request a refund via a webform, requiring a photo of the product before disposal. No incidents or injuries were reported at the time of the announcement.
Widespread Media Coverage of the Afrin Recall
News outlets across the U.S. began widely reporting on the Afrin nasal spray recall, informing the public about the child safety risk and refund process.
Ongoing Recall Efforts and Consumer Action
As of this date, the recall remains active. Consumers continue to be urged to check their travel-size Afrin Original Nasal Spray 6 mL bottles against the provided lot numbers and seek refunds. Bayer is working to reintroduce compliant products.
🔍Deep Dive Analysis
The 'Afrin Recall' primarily refers to a significant voluntary recall initiated by Bayer HealthCare LLC on April 30, 2026, in cooperation with the U.S. Consumer Product Safety Commission (CPSC). This recall involves approximately 786,100 unexpired 6 mL travel-size bottles of Afrin Original Nasal Spray. The core issue stems from the product's packaging, which was found to be non-compliant with the Poison Prevention Packaging Act (PPPA). Specifically, the bottles lacked child-resistant packaging and did not feature the mandatory front-label statement indicating that the package is not child-resistant.
The active ingredient in Afrin, oxymetazoline, is an imidazoline, which can cause serious injury or illness if swallowed by young children. The absence of child-resistant features and proper warnings created a significant safety hazard, leading to the recall. The affected products were sold at various retailers, primarily convenience stores and travel hubs like airports, from September 2024 to April 2026, retailing for about $7 to $9.
While this 2026 recall is the most prominent 'Afrin Recall' event, it's important to note that other recalls involving oxymetazoline hydrochloride nasal sprays (the active ingredient in Afrin) have occurred in the past, though not directly branded as 'Afrin' or by Bayer. For instance, in December 2023, a recall for oxymetazoline hydrochloride nasal spray was initiated due to possible microbial contamination in the purified water used during manufacturing, although no contamination was found in the final products. Earlier, in March 2004, a manufacturer's recall of an over-the-counter oxymetazoline HCl 0.05% nasal spray was issued due to contamination with Burkholderia cepacia complex, posing serious infection risks, particularly for immunocompromised individuals.
As of May 3, 2026, Bayer and the CPSC have reported no incidents or injuries directly related to the 2026 Afrin recall. Consumers who possess the recalled 6 mL travel-size bottles are instructed to immediately secure them out of reach of children and visit Bayer's dedicated recall webform to request a refund. They are required to submit a photo of the product before disposing of it. Bayer has also informed its distributors and retailers and is working to ensure that compliant products with appropriate child-resistant packaging and labeling are available in stores soon.
What If...?
Explore alternate histories. What if Bayer Afrin Original Nasal Spray 6 mL Travel Size Recall made different choices?